Genetic and biochemical evidence has established that the E2 open reading frame (ORF) of bovine papillomavirus type 1 encodes at least two different site-specific DNA-binding proteins, one which activates and the other which represses expression from a viral promoter (P. F. Lambert, B. A. Spalholz, and P. M. Howley, Cell 50:69-78, 1987 
The life cycles of the DNA viruses which infect animal cells can be broadly placed into two categories. Some DNA viruses infect cells and rapidly enter into productive replication with ensuing cell death, while others establish their genomes as episomes and have a long latent period. (We use the word episome to mean an added genetic element which can reproduce itself in the cell in different ways depending on the nature of the element and the cell type. Thus the word episome can refer to an element acquired by infection which is carried by the cell in an integrated state or as a plasmid. For further details, see reference 20.) This latency even persists through many cell divisions if the infected cells are dividing or are induced to proliferate by virally encoded gene products. The viruses which cause warts are interesting members of this latter class because the viral episomes establish as stable nuclear plasmids and must replicate their genomes in coordination with the cell through a large number (54) of cell divisions. Bovine papillomavirus type 1 (BPV-1) in particular causes massive fibropapillomas soon after infection (25) , and in these cells the viral genome is carried as a high-copy-number plasmid. Vegetative and exponential replication of this virus, however, occurs only in terminally differentiated keratinocytes. Thus, a highly regulated process coordinating viral gene expression and cell state must play a major role in the maintenance of latency. Along these lines, it is thought that a major viral promoter (PL) is active only in differentiating keratinocytes (2) .
We have been interested in the study of BPV-1 plasmid replication with the view that an understanding of how the replication system is regulated might give some clues into how transcription and replication processes interplay in eucaryotes. The rodent C127 cells provide what we optimistically believe to be a good model for this latent plasmid replication in vivo. Viral infection of the cells leads to oncogenic transformation with single-hit kinetics (11) , and the viral genome is carried as a stable multicopy nuclear plasmid (26, 27) . The facts that the virus transforms with single-hit kinetics and that the copy number of 100 to 200 is detectable after only a limited number of cell doublings imply that an initial amplification of viral DNA occurs before a stable regulated copy number is achieved. This concept is reinforced by transient replication studies (28) which indicate that viral DNA replicates faster than cellular DNA upon initial entry into the cell. After establishment, the viral copy number stays constant.
The genetic analysis of the BPV-1 genome reveals that a large network of viral factors and promoters must interact to achieve the switch from this initiation mode of replication to the homeostasis apparent in the transformed cells. The somewhat surprising feature of this system seems to be its complexity, as at least six different gene products are included in this process. How these factors interact in a kinetic sense and in maintenance has not (4, 29) is absolutely required for transient replication and has been postulated to therefore play a direct role in viral replication (4 (4, 29) . Furthermore, Roberts and Weintraub (39) (27) . Plasmids used as probes for the RNase protection experiments and for in vitro transcription are described in the figure legends. S1 nuclease and RNase protection analysis of RNA. For S1 nuclease, RNase protection, and primer extension analysis of in vivo RNA, poly(A)-selected cytoplasmic RNA was prepared as described previously (5). Unless otherwise indicated, cells were treated with 30 p,g of cycloheximide per ml for 4 h prior to being harvested. S1 nuclease analysis was carried out as described elsewhere (13) . Preparation of uniformly labeled SP6 probes and RNase protection analysis were performed as described previously (33) , with the following modifications. Hybridizations were carried out in 40 mM PIPES (piperazine-N,N'-bis(2-ethanesulfonic acid) (pH 6.7)-0.4 M NaCl-1 mM EDTA in a final volume of 30 ,ul. Following denaturation for 5 min at 85°C, hybridizations were carried out at 68°C for 3 h. RNase digestions were performed at 25°C for 30 min unless otherwise indicated. All digestion products were fractionated on 5% denaturing polyacrylamide gels. Cordycepin A sequencing ladders were made by preparing uniformly labeled SP6 probes as described previously (33) in the presence of 125 p.M dATP.
In vitro transcription and primer extension. Primer extension was performed as described elsewhere (46) . Whole-cell extracts of HeLa cells were prepared as described previously (31) , and in vitro transcription was carried out by the procedure of Dynan and Tjian (12 (22) . cDNAs were synthesized via modifications of the standard protocols (35), using oligo(dT) as a primer for first-strand synthesis, and the library size, which was measured to be 1.5 x 106, was subsequently amplified once (see Materials and Methods).
To screen this library for cDNAs which might represent El transcripts, the series of hybridization probes shown in Fig. 1 below a physical map of the early region of BPV-1 were constructed. The location of the probes with respect to the ORFs of the early region are shown and in the legend to Fig. 1B , the precise BPV-1 nucleotide positions are given. Previous RNA mapping experiments indicated that a BPV mRNA exists which contains an exon encoded by a 5' portion of the El ORF (47) . As outlined in the introduction, we were interested in obtaining cDNAs which might encode for the M gene and thus RNAs with coding sequences from this 5' El region were sought. Toward this end, we used the PE8 probe in a primary screen of the library. Approximately 0.01 to 0.05% of the lambda plaques hybridized to this probe. The abundance of such inserts was approximately two-to threefold lower than those frequencies estimated with the PE6 probe.
Forty-five PE8-positive plaques were picked, and the inserts were then analyzed in detail. The first characterization was to hybridize the cDNAs with each of the probes shown in Fig. 1B . The inserts were thus classified into major groups according to their hybridization profiles. 
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The most abundant such family of cDNAs obtained by this primary screen is represented by clone N7-3 ( Fig. 1C) . Twenty-four such clones were obtained. These cDNAs hybridized only to the PE8 and PPA probes. Clones of the N7-3 family had 5' ends clustered between BPV-1 nucleotides 900 to 1000. These clones terminated, as did all others in our study, at a 3' position of 4203 followed by a poly(A) tail. cDNA clones with the hybridization profiles of N7-1 were obtained eight times while those of the J9-3 family were obtained seven times. All others were obtained as unique members.
The cDNAs that are believed to be generated by common promoters are grouped together in Fig. 1 . As discussed below, we believe it is likely that abundant clones J9-3 and N7-3, as well as the relatively rarer clones N15-2 and N12-2, represent RNAs produced from a previously unreported To obtain other clones containing sequences from the URR, two separate primary screens of the library were done, using the PP1 and PE9 probes. With both probes, two million bacteriophage were independently screened. P19-1 was obtained (Fig. 1C ), which has a structure very similar to that of N19-1, although a different acceptor links the position 7385 URR donor to the downstream coding sequences. Three other clones, 27-3 through N16-1, were also characterized. Two clones, 27-3 and 26-1, both have 5' ends at precisely the same nucleotides. This position 7438 is at the end of a T8 stretch in the coding strand and may represent a hot spot for cleavage with RNase H in the preparation for second-strand cDNA synthesis, thus creating artificially the chance for common 5' ends in a family of cDNAs.
We will discuss in another section of this article the potential coding capacities of the various cDNAs described here. However, at this point it is interesting to point out that with the possible exception of cDNA clone J9-3, no cDNAs specifically isolated could encode for the R gene and only this clone contained a nucleotide sequence between positions 1940 and 2558. This is particularly intriguing as mutational data mentioned above shows that mutations at BPV-1 position 2113 inactivate transient as well as stable plasmid replication. To directly screen for cDNAs which might contain sequences from this region, we probed the cDNA library with the probe PE1J (Fig. 1B) . From a screen of more than 5 x 106 phage, no BPV-1 cDNAs were found that did not fall into the families defined by J9-3, J6-1, or J9-2.
To summarize this structural information briefly, a large number of new donor and acceptor sites within BPV-1 have been established by these cDNAs, and the sequences found at these sites are shown in Fig. 2 . Initially, we did not expect to find such a large number of different types of cDNAs which spanned the 5' end of the El ORF. However, recently published Northern (RNA) blot analysis of BPV-1 RNAs with probes similar to those used here (6, 46) (47) . However, the complexity of the genetic organization of the virus in this region is illustrated by the findings reported here that this donor can join exons to either the most commonly used acceptor in the virus at position 3225 (2, 51) or to acceptors at nucleotide 1866 or 2558.
Identification of a promoter within the El ORF. The abundant cDNAs described in the previous section all have their 5' ends near the beginning of the El ORF. Nevertheless, it is impossible to prove via cDNA cloning where the bona fide 5' ends of the actual RNAs are by this sort of analysis. Even with model systems such as globin 9S mRNA, methods which enrich for full-length clones generally yield cDNA which are truncated at their 5' ends (36) . We had anticipated that the RNAs represented by the cDNA clone N7-3 would be initiated by a promoter close to the beginning of the El ORF. Alternately, these RNAs could be initiated upstream and a small exon generated by splicing might have been lost in cDNA synthesis. This assumption was based on the facts that the cDNA inserts in the library were large and that sequence analysis of cDNAs from known abundant BPV-1 RNAs terminated close to known start sites (data not shown). Thus, to determine where the likely initiation sites are, it was necessary to analyze in vivo RNA by a variety of nuclease protections and primer extension methods.
A series of probes either 5' end labeled or uniformly labeled were used, and their structures are displayed in Fig.  3 . First, a DNA fragment from nucleotides 576 to 1010 was 5' end labeled on the noncoding strand and was annealed to cytoplasmic poly(A) RNA from ID13 or C127 cells and was digested with Si nuclease (Fig. 3) . Two To further extend the notion that a stable 5' end maps to these nucleotides, a plasmid containing the BPV-1 PstI fragment from nucleotides 576 to 1299 was assayed in vitro for promoter activity in whole-cell extracts of HeLa cells in the presence or absence of 4 ,ug of a-amanitin per ml. This is a level of drug which inhibits RNA polymerase II transcription in vitro. The in vitro products were analyzed via primer extension analysis as described for the in vivo RNA. The in vitro products produced by this fragment have the same 5' ends as do the in vivo RNA, and their synthesis is sensitive to the RNA polymerase II inhibitor (Fig. 4) . We will hereafter refer to this region of DNA as the P3 promoter, using the convention from our laboratory first described for the P1 promoter (46) . We use this convention rather than naming the promoter after putative cap sites (2) for two reasons. First, promoters usually refer to cis-acting regulatory sequences and we assume that the starts at nucleotides 886 and 896 share common cis control elements. Second, for very heterogeneous ends (e.g., those around nucleotide 2440), it is extremely cumbersome to label each nucleotide as a promoter. The disadvantage, of course, is that new promoters which may be found would require different names since the order from P1 would be shifted.
To determine the structure of the exons of the mRNAs initiating at the P3 promoter, a series of RNase protection experiments were performed, using the uniformly labeled cRNA probes depicted in Fig. 3 . Cytoplasmic poly(A) RNAs extracted from ID13 or C127 cells were hybridized to an SP6 polymerase-generated probe which contained BPV-1 sequences from nucleotides 576 to 1299 (probe II in Fig. 3 ).
After treatment with RNase A and RNase T1, the protected fragments were separated by electrophoresis. The autoradiogram of this gel is shown in Fig. 5A ; lane C is the C127 control, and lanes A and B are identical experiments except for the RNase digestion conditions. By the mobilities of the fragments we could tentatively ascribe each band to a particular transcript. The model for these assignments is shown diagrammatically in Fig. 3 . The topmost protected band is attributed to full-length probe protection and represents unspliced (within the probe region) RNAs; this band is unlabeled. The next band down represents RNAs initiating upstream of the 576 position and splicing at 1235; RNAs such as cDNA clone N7-1 and 12-4 would generate such bands.
The two bands labeled P3b and P3a correspond to fragments produced by transcripts initiating at nucleotides 886 and 896 and splicing at nucleotide 1235; specifically, the length of these bands corresponds to 338 and 348 nucleotides, the length from the P3 promoter to the donor. The most frequent cDNA clone that we obtained in our screen N7-3 would generate such fragments, and these results corroborate those findings. The band labeled 576-865 is ascribed to all RNAs initiating upstream of 576 (e.g., E6 and E6-7 messengers) which use the 865 donor (47, 51) . To test these assignments, probe II was halved to generate SP6 probes III and IV. Each of these probes was annealed to cellular RNAs and was analyzed. The predicted fragment lengths were detected with each probe (Fig. SB) Fig. 5A .) This number agrees reasonably with the results of the cDNA cloning experiments described above. Furthermore, a significant number of transcripts probably initiate at P2 and generate RNAs which use the 1235 donor (e.g., N7-1). This can be estimated from the band labeled 576-1235 in Fig. 5A .
As the RNAs used as templates for cDNA synthesis were prepared from cycloheximide-treated cells, it was of interest to address the question of whether drug treatment changes qualitatively the RNA profile in this region. The results (Fig.  5C) show that no qualitative differences can be discerned, although there is a large increase in signal specifically from the P3 promoter with cycloheximide treatment. (Note that 10-fold more RNA was used in the cycloheximide-minus experiment.) Clone N7-3 encodes a repressor of BPV gene expression. trol, to assess both the trans effects of the repressor vector due to its potential protein production, as opposed to promoter competition effects, and to test the notion that the specific protein is an E8/E2 fusion, the clone CMV E8*/E2 was constructed (Fig. 6) . By oligonucleotide-directed mutagenesis, the leucine codon (TTA) at position 1223 was changed to a termination codon (TAA). This single point mutation eliminates only the coding potential of all E8 proteins in the vector and leaves intact possible expression from other frames. (The transversion introduces a silent mutation in the El ORF).
We first asked if the CMV E8/E2 vector could repress the transactivation of the E2 product upon the inducible enhancer in the BPV-1 control region (23, 24, 49) . Figure 7A shows the reporter plasmid, URR CAT, which provides the cis-binding sites for the E2 products, and the plasmid pUC C59, which provides the transactivator for the reporter. pUC C59 is a derivative of the C59 E2 vector kindly provided by P. M. Howley (51). The URR CAT construct can produce the protein CAT, and its activity can be quantitatively assayed as described elsewhere (14) . All transfections were carried out by using HeLa cells as recipients, and the results of the CAT assays are shown as raw data in Fig. 7B Fig. 7B . This effect is measured to be at least fivefold (Fig. 7C, 6 .7% conversion in contrast to 1.3% conversion) and clearly is not due to artifactual plasmid competition since the point mutant construct CMV E8*/E2 has no effect on the reporter. The next three experiments (Fig. 7B) repeat the classic transactivation experiments which show that even at very low doses the E2 vector can evoke a large stimulation of the ability of the BPV URR to promote gene expression (16, 17, 45, 48) . In our hands in this particular system, the stimulation is about 10-fold. The results shown illustrate that the E2 stimulation saturates at levels below or at 0.1 ,ug of transactivator vector. We next mixed together reporter CAT vector, saturating levels of transactivator E2 (0.1 p.g), and increasing levels of the test plasmid CMV E8/E2. As shown, the CMV E8/E2 construct counteracts the trans-positive effects of E2 and lowers the basal activity of the reporter. Again, the CMV E8*/E2 vector has no effect in this type of triple mixing experiment (e.g., BPV URR CAT, pUC C59, and CMV E8*/E2), illustrating that the negative effects of the repressor vector must be due to the trans action of its product. Overexpression of a protein which can counter the effects of the E2 protein would be expected to interfere with BPV-1 focus-forming capacity (23 (Fig. 8) .
DISCUSSION BPV-1 has a relatively small genome, yet a large portion of the sequence has not been found expressed as mRNA. Most conspicuously missing from the maps of RNAs produced in either productively infected fibropapillomas or latently infected cultured cells are mRNAs from parts of the highly conserved El ORF and from the URR. Together these two regions constitute more than one-third of the 8-kb genome. As trans-acting gene products have been defined genetically for the El ORF, it is generally assumed that the reason for this lack of detection is the low abundance of these transcripts. Using specific probes from both the El ORF and the URR, we have been able to isolate and characterize a variety of new cDNAs and define a new transcription unit in the virus.
The main points of this article concern the functional and structural analysis of the transcripts from the P3 promoter. The major transcript from this promoter encodes a repressor, and from the results presented above we estimate that it is as abundant as the individual transcripts from the upstream promoter P2. This estimate is based on both the frequency of clones such as N7-3 relative to E6 clones in the library and on the direct RNA mapping data shown in Fig. 5 . Before we discuss specific results relevant to the rarer cDNAs, two caveats should be mentioned. First, we used cyclohexamide prior to harvesting cellular cytoplasmic RNA to increase our chances of obtaining mRNAs which might be degraded rapidly or expressed rarely. The block to protein synthesis which slows down mRNA degradation increases BPV-1 transcript abundance but potentially augments very weak promoters (e.g., the P1 promoter) by lowering repressor levels. Thus, we may have obtained cDNAs in some cases which are extremely rare in stably transformed cells. We do not, however, know of a situation wherein the drug creates new promoters or causes aberrant splicing. A second limitation concerns the promoter assignments for the rare cDNAs. As the cDNAs were in general truncated by 50 to 300 base pairs, it was relatively straightforward for cDNAs such as N7-3 to be assigned to promoter P3, for we obtained many cDNAs of this type, all of which had 5' ends close to the mapped P3 end. Furthermore, we could map an exon of expected size with RNase protection experiments by using RNAs harvested from non-drug-treated cells. However, for cDNAs obtained only once (e.g., 26-1 and 27-3), the promoter assignment is clearly speculative and is simply based on our current knowledge of BPV-1 promoters. Thus in all cases we ascribed the nearest 5' promoter to a given cDNA.
The P1 promoter is weakly expressed from stable plasmids in ID13 cells (2, 46) , and several of the cDNAs characterized here are likely to be expressed from this promoter ( Fig. 1; see Fig. 9 ). In particular, P19-1 can be conceptually translated to yield an E7 protein. This 102-amino-acid peptide would utilize an ATG codon just two codons upstream of the nucleotide 7385 donor sequence. Given the central role that E7 plays in human papillomaviruses (38, 42 ; Banks and Crawford, personal communication), it is possible that such a protein might be involved in some stage of the BPV-1 life cycle. Recently we have found that certain BPV-1 mutations in the P1 promoter reduce transformation frequencies of the DNAs (G. L. Bream and M. Botchan, unpublished results) and that these mutants can be complemented by the expression of the P19-1 cDNA. Whether this effect is due to only the direct effect of E7 or to the effect of the genes on copy number stability is not known. The cDNA 27-3, which uses the same E7 acceptor site as P19-1, cannot encode such a protein since in-frame terminators exist 5' to the E7 ORF in this cDNA and no in-frame ATGs are present in E7. The cDNA clone 27-3, however, has the capacity for a small 100-amino-acid 5 Point mutations in the E8 ORF either 5' or 3' to the splice donor at 1235 lead to BPV DNAs which integrate in focus assays. If one assumes that both J6-1 and J9-2 are truncated cDNAs whose RNAs initiated from P3, either of these products could code for an E8 protein. Indeed, these E8 mutations can be complemented by a vector which carries a surrogate promoter linked to clone J6-1 (Fig. 1) if the E8 ATG start region is reconstructed.
One of the major objectives of our cDNA screen was to find clones which could represent putative mRNAs for the M gene product. We had anticipated that either a small exon would be spliced in frame into the El ORF or that a promoter would be found just 5' to the ORF. This is because the limited genetic studies on the M gene define coding sequences up to the 5' end of the ORF (29). Chow et al. bles the BPV-1 species (2b) characterized by Stenlund et al. (47) . While our data cannot exclude the existence of such an analogous promoter at the end of the El ORF, our data do show that such a message must be at least 10-to 20- 40 polyomaviruses, and it makes perfect sense that viruses with long latencies, such as BPV-1, should have such systems. If one assumes that a single bovine wart with a mass of 1.5 kg is the result of one viral infection, this leads to the calculation that the virus must maintain its latency in a transformed cell through at least 43 cell doublings. A complicated circuitry of factors and cis-regulatory sites might be presupposed to exist to ensure continued growth of such a massive structure. Thus, the problem of maintaining homeostasis with regard to cell division is a much more important problem in vivo than is usually addressed in focus formation and expansion to a cell line in culture in which routinely only 20 to 25 cell divisions occur before analysis. We can formally suggest two discrete but not exclusive reasons for why the two different forms of the repressor gene are arranged the way they are in BPV-1. On the one hand, the proteins predicted by their gene structures are different and thus they may have different functions. Both proteins have a common 204-amino-acid carboxy terminus and diverge at an amino-terminal domain defined by the acceptor site at BPV-1 nucleotide 3225 (Fig. 9) . The amino terminus of the E8/E2 protein has 11 amino acids from an upstream exon while E2TR has an additional 35 amino acids which are encoded by a continuation of the E2 ORF 5' to the acceptor. Another difference between the proteins may involve their putative interactions with cellular factors mediated by their amino-terminal domains. We might point out that overexpression of either of the gene products for repressor function through surrogate promoters may obscure differences in function between the two proteins. For example, one protein may have higher affinities for a particular binding site than does another, and overexpression might cancel such differences. These points focus on structural differences in the proteins. Alternatively, as the repressor genes are linked to separate promoters, they are perhaps independently regulated. Thus, one or the other gene may function as the important negative regulator in a particular cell type (or time in the cell cycle). Thus, much more work must be focused on how these promoters for the repressors are expressed and where these proteins are expressed in situ, and more specific assays (e.g., with different promoters) may be called for to distinguish the putative differences between the genes. Interestingly, the recent work of Hubbert et al. (19) shows via serological methods that both forms of the repressor protein coexist in unsynchronized cultures of virus-transformed cells. These workers have shown that the E2TR (or long form of the repressor protein) is more abundant than is the E8/E2 form in the C127 cell system. Finally, it is possible that the putative different functions of the genes alluded to above cannot be addressed in short-term cultures of heterologous mouse cells. In this system, either repressor may suffice to maintain appropriate levels of gene expression.
We were surprised to find cDNA clone N15-2 because it encodes for a function which is antagonistic to the function of the E8/E2 repressor gene regulated by the action of the P3 promoter. As indicated in Fig. 9 , the potential promoter indicated for clone N15-2 is the P3 promoter; this clone can code for the entire E2 ORF since the splice acceptor at nucleotide 2558 is just upstream of the likely ATG initiator codon in E2. Moreover, recent unpublished work with N15-2 shows that it can functionally make an E2 transactivator when linked to surrogate promoters (P. Vaillancourt, J. Choe, and M. Botchan, manuscript in preparation). However, by far the bulk of the RNAs initiated from P3 must splice from the common donor at nucleotide 1235 to the acceptor at 3225 rather than to the acceptor at nucleotide 2558. Thus, splicing as well as promoter utilization may contribute to the balances between positive and negative factors. Similarly, the vast majority of starts from P4 splice to yield a putative E5 message (1, 18, 47, 51) , and it is questionable whether the bulk of the E2 protein is indeed expressed from this promoter. Stenlund et al. (47) characterized a BPV RNA (their species 3) which links the internal E6 donor to an acceptor just upstream of the E2 ORF, and we may speculate, on the basis of the relative abundance of this transcript, that the P2 promoter may be the strongest contributor to the production of the transactivator E2. Again, however, we would like to emphasize the extremely low abundance of RNAs such as N15-2 and point out that genetic studies assessing the role of the acceptor at nucleotide 2558 will be needed to begin to test critically the complexities implied by Fig. 9 . In summary, then, the structurally different transcriptional repressor proteins seem to be expressed from two different promoters while the putatively unique activator may be expressed from three different promoters. While on the surface it may seem bewilderingly complex to have so many different ways to express similar activities, given the complexity of the life cycle of the virus mentioned above and the range of cell types it can infect, this is perhaps expected. Recent findings on the expression patterns of a single cellular locus which codes for a family of transcription factors shows a similar level of complexity (41) .
If the plethora of promoters and trans factors discussed above does not as yet describe a transcriptional regulatory system for the BPV-1 genome, some of the complexities concerning BPV-1 E2 genetics may be clarified by the discovery of the E8/E2 gene. Lusky and Botchan (28) showed that an E2 mutant, d1211, was severely crippled in a transient replication assay. Moreover, in side-by-side assays, the mutant BAL15 replicated transiently as efficiently as did wild-type BPV-1 even though it is deleted for all of the E2 ORF (Lusky and Botchan [29] (Fig. 9) . C59 cannot provide an E8/E2 product and thus might not be expected to complement any E2 mutants which affect this member of the E2 family.
Furthermore, it is conceivable that the C59 cDNA may not provide E2 itself in precisely the right way. Perhaps E2 provided by P2 or P3 is needed to achieve most-efficient virus transformation and plasmid establishment.
